Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 20, 2026.

Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration

Jose L. Labandeira-Garcia, Ana I. Rodríguez-Perez, Pablo Garrido-Gil and 3 more

Frontiers in Aging Neuroscience · 2017 · Review

doi:10.3389/fnagi.2017.00129

Abstract

Microglia can transform into proinflammatory/classically activated (M1) or anti-inflammatory/alternatively activated (M2) phenotypes following environmental signals related to physiological conditions or brain lesions. An adequate transition from the M1 (proinflammatory) to M2 (immunoregulatory) phenotype is necessary to counteract brain damage. Several factors involved in microglial polarization have already been identified. However, the effects of the brain renin-angiotensin system (RAS) on microglial polarization are less known. It is well known that there is a "classical" circulating RAS; however, a second RAS (local or tissue RAS) has been observed in many tissues, including brain. The locally formed angiotensin is involved in local pathological changes of these tissues and modulates immune cells, which are equipped with all the components of the RAS. There are also recent data showing that brain RAS plays a major role in microglial polarization. Level of microglial NADPH-oxidase (Nox) activation is a major regulator of the shift between M1/proinflammatory and M2/immunoregulatory microglial phenotypes so that Nox activation promotes the proinflammatory and inhibits the immunoregulatory phenotype. Angiotensin II (Ang II), via its type 1 receptor (AT1), is a major activator of the NADPH-oxidase complex, leading to pro-oxidative and pro-inflammatory effects. However, these effects are counteracted by a RAS opposite arm constituted by Angiotensin II/AT2 receptor signaling and Angiotensin 1-7/Mas receptor (MasR) signaling. In addition, activation of prorenin-renin receptors may contribute to activation of the proinflammatory phenotype. Aged brains showed upregulation of AT1 and downregulation of AT2 receptor expression, which may contribute to a pro-oxidative pro-inflammatory state and the increase in neuron vulnerability. Several recent studies have shown interactions between the brain RAS and different factors involved in microglial polarization, such as estrogens, Rho kinase (ROCK), insulin-like growth factor-1 (IGF-1), tumor necrosis factor α (TNF)-α, iron, peroxisome proliferator-activated receptor gamma, and toll-like receptors (TLRs). Metabolic reprogramming has recently been involved in the regulation of the neuroinflammatory response. Interestingly, we have recently observed a mitochondrial RAS, which is altered in aged brains. In conclusion, dysregulation of brain RAS plays a major role in aging-related changes and neurodegeneration by exacerbation of oxidative stress (OS) and neuroinflammation, which may be attenuated by pharmacological manipulation of RAS components.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

In the late 19th century, Franz Nissl first described microglia as staebchenzellen (rod cells) for their rod-shaped nuclei. In 1913, Santiago Ramón y Cajal described these cells as a “third element”, and in 1919 microglial cells were characterized by his disciple Pío del Río Hortega as a phagocytic and distinct non-neural and non-astrocytic population. During embryonic development, primitive yolk sac myeloid progenitors enter the brain and differentiate into microglial cells (Alliot et al.,; Ginhoux et al., ). It is usually estimated that around 10% of the adult brain cells are microglial cells (Carson et al.,; Kettenmann et al., ). In the adult mouse brain, microglia constitute 5%–12% of all glial cells, although these cells are not evenly distributed throughout the brain, ranging from 5% in the cerebral cortex to 12% in the substantia nigra (Lawson et al.,; Mittelbronn et al.,; Harry and Kraft, ). There are tissue-specific macrophages in practically all tissues of the body (Gautier et al., ), and microglial cells have been considered as the resident macrophages in the brain. Consistent with this, the resident microglia mediate the brain immune and inflammatory responses (Hu et al.,; Prinz and Priller, ). Although microglia and brain macrophages express several common protein markers, microglial cells have a particular molecular signature, which is different to other circulating and tissue-resident macrophagic cells (Hickman et al.,; Butovsky et al., ).

Microglial cells have been classically described to exist in two states, resting and activated state. In the healthy brain, neurons produce several immunosuppressive proteins, which keep microglia in a classical inactivated state (Harrison et al.,; Hoek et al., ). However, the initial concept of resting microglia has been modified, and recent studies have shown that the classical “resting” microglia are highly active by scanning of the surrounding region for disturbances in physiological conditions (Davalos et al.,; Nimmerjahn et al., ). Furthermore, it is now generally admitted that the term activation includes a set of several “activated” states. The classical concept of either “good” or “bad” activation states of microglia has to be reconsidered, and substituted by a range of different types of functional activation. Microglia can develop a number of different phenotypes and functions to preserve brain homeostasis depending on their environment.

Microglial Polarization

The dual role of microglia is associated with different polarization of microglia under different context, particularly after brain injury (Hu et al.,; Franco and Fernández-Suárez,; Kim et al., ). Microglia can develop into proinflammatory/classically activated (M1) or anti-inflammatory/alternatively activated (M2) phenotypes depending on the signals present at different stages after brain lesions. M1/proinflammatory microglia produces proinflammatory mediators and free radicals that exacerbate neuronal death. Alternatively, M2/immunoregulatory microglia induce brain repair and regeneration, produce growth factors and anti-inflammatory cytokines to protect neurons and resolve inflammation. In addition, as primarily described in the periphery, several subclasses of M2/immunoregulatory activation have been identified. The M2a activation state has a main function of suppression of inflammation. A second state of alternative activation is classified as “M2c”, which has been suggested to restore the tissue after the inflammatory process has been attenuated (Gordon,; Colton,; Sica and Mantovani, ). The class termed “M2b” is least understood; M2b has been involved in both pro- or anti-inflammatory responses and related to memory immune responses (Mantovani et al.,; Edwards et al., ). The functional polarization of microglia is modulated by several receptors, transcription factors, acute phase proteins, and metabolic states. Toll-like receptors (TLRs), nucleotide-binding oligomerization domains (NODs) and NOD-like receptors are known to play a major role in microglia-mediated inflammation (Ransohoff and Perry,; Ransohoff and Brown, ). Upregulation and release of reactive oxygen species (ROS) and activation of inducible nitric oxide synthase (iNOS), followed by the release of reactive nitrogen species (RNS), are hallmarks of M1 macrophages/ microglia (MacMicking et al., ). Upregulation of the enzyme arginase 1 (Arg1) is considered as an specific marker of M2 macrophages/microglia (Sica and Bronte,; Chhor et al., ).

An adequate progression from the proinflammatory/M1 to immunoregulatory/M2 phenotype is necessary to efficiently counteract brain lesions. However, when this process is dysregulated, the persistent release of inflammatory cytokines and ROS induces neuron death and enhances brain damage (Kigerl et al., ). Interestingly, microglial activation and enhanced neuroinflammatory responses have been observed in major neurodegenerative diseases (Frank-Cannon et al., ). Persistently proinflammatory polarized microglia and release of proinflammatory cytokines leads to a pro-oxidative and proinflammatory milieu and enhances neurodegeneration (Heneka et al.,; Tang and Le, ). New therapeutical strategies are necessary to modulate microglial activation and drive microglia polarization to a protective phenotype (Koenigsknecht-Talboo and Landreth,; Porrini et al., ).

Proinflammatory phenotype polarization can be induced by stimulation with compounds such as the TLR-4 agonist lipopolysaccharide (LPS), interferon (IFN)-γ, Interleukin (IL)-17A and tumor necrosis factor-α (TNF)-α. Alternatively, stimuli such as IL-4, IL-10, or transforming growth factor β (TGF)-β induce the M2/immunoregulatory phenotype. However, the effects of the brain renin-angiotensin system (RAS) on microglial polarization are less known. It has been shown that angiotensin modulates immune cells in peripheral tissues, and that inflammatory cells have all RAS components, including angiotensin II (Ang II). Ang II receptor antagonists are modulators of macrophagic polarization in different tissues such adipose tissue, lung, kidney, or tumors (Fujisaka et al.,; Ma et al.,; Liu et al.,; Shrestha et al., ). There are also recent data showing that brain RAS plays a major role in microglial polarization.

The Renin-Angiotensin System

The RAS was initially considered as a circulating humoral system, with functions in regulating blood pressure and in sodium and water homeostasis. Ang II, which is the most important effector peptide of the RAS, is formed by the sequential action of two enzymes (renin and angiotensin converting enzyme, ACE) on angiotensinogen. Ang II acts via type 1 and 2 (AT1 and AT2) receptors (Unger et al.,; Oro et al.,; Jones et al., ). AT1 and AT2 receptors have usually opposite effects on several cell functions (Chabrashvili et al.,; Jones et al., ). A number of data suggest, however, that interactions between AT1 and AT2 receptors may be more complex, and additional studies are necessary. Furthermore, new RAS components have emerged, which appear to contribute to further regulate the system (see below; Figure 1).

In addition to the “classical” circulating RAS, a second RAS (local or tissue RAS) has been observed in several tissues. A local independent RAS has also been observed in the brain (Ganong,; Re, ). The local systems have all components observed in the circulating RAS. The local Ang II plays a relevant function in pathological changes of the corresponding tissues (Ruiz-Ortega et al.,; Suzuki et al., ). Tissue Ang II, via AT1 receptors, induces oxidative stress (OS) damage by activation of the NADPH-oxidase complex (Nox; Touyz,; Garrido and Griendling, ). In different types of cells, PKC mediates initiation of AT1-induced Nox activation (Plumb et al.,; Herrera et al., ), which was also confirmed in microglial cells (Joglar et al., ). However, this initial generation of superoxide/H2O2 activates multiple downstream signals and transcription factors that may further amplify Nox oxidase activity in a multistep process that remains to be totally clarified (Seshiah et al.,; Balakumar and Jagadeesh, ). Consistent with this, we have recently shown that Nox-derived superoxide activates NFκB and the RhoA/Rho kinase pathway in microglial cells, which further increased Nox activation via p38 MAPK (Borrajo et al.,; Rodriguez-Perez et al., ).

More recent studies on local RAS have identified new components and mechanisms controlling RAS effects (Figure 1). New ACE homologs such as ACE2 and Chymase have been observed in different cells and tissues (Bacani and Frishman,; Hamming et al., ). In addition to Ang II, several angiotensin peptides such as Ang (1–7), Ang III and Ang IV have been shown to have functional effects. Ang IV may act via specific AT4 receptors (Albiston et al., ). Ang (1–7), via a G-protein coupled receptor Mas (Santos et al., ), may counteract the effects of activation of AT1 by Ang II (Clark et al.,; Kostenis et al., ). A specific receptor for renin and its precursor prorenin (prorenin/renin receptor, PRR) may be of particular interest for the brain RAS (Nguyen et al., ). High levels of PRR were found in heart, brain, placenta and adipocytes, and lower level of expression in other tissues (Nguyen, ). PRR play a dual function (Nguyen and Contrepas,; Shan et al., ): (i) Ang II-mediated effects; after binding to PRR, the catalytic activity of renin to hydrolyze angiotensinogen into angiotensin increases by about 4–5 times, and the precursor prorenin acquires catalytic properties similar to those of renin and (ii) Ang II-independent actions; PRR trigger their own signaling pathway that leads to pro-oxidative effects similar to those induced by activation of AT1 receptors.

The Brain RAS

Initially, it was considered that the effects of RAS in the CNS were a consequence of the activity of the circulating RAS, acting through the circumventricular organs, on neurons regulating blood pressure and sodium and water homeostasis (Phillips and de Oliveira, ), because active components of the RAS, particularly Ang II, do not cross the blood-brain barrier (Harding et al., ). However, a local and independent RAS has now been identified in the brain. Astrocytes are the major source of brain angiotensinogen (Stornetta et al.,; Milsted et al., ), with only a small contribution from neurons (Kumar et al.,; Thomas et al., ).

Different RAS components were observed in several brain regions. In the basal ganglia, particularly in the nigrostriatal dopaminergic system, we have shown a local RAS using laser confocal microscopy and other methods such as in situ hybridization, laser microdissection and PCR or western blotting. In the substantia nigra, both AT1 and AT2 receptors were observed in dopaminergic neurons, astrocytes and microglia of rats (Rodriguez-Pallares et al., ), mice (Joglar et al., ), non-human primates (Valenzuela et al.,; Garrido-Gil et al.,, ) and human brains (Garrido-Gil et al., ). In addition, AT1 and AT2 receptors were observed in dopaminergic neurons and glial cells in primary cell cultures of the nigral region and several neuronal and glial cell lines (Rodriguez-Pallares et al.,,; Joglar et al.,; Rodriguez-Perez et al., ). In some studies, expression of AT1 receptors was not detected in microglial cells (Benicky et al., ). However, it is known that the level of microglial AT1 receptor expression is low in control (classically non-activated) microglia and is highly upregulated as part of the pro-inflammatory microglial response (Miyoshi et al.,; Rodriguez-Perez et al.,; Dominguez-Meijide et al., ). Detection of AT1 expression may depend on the sensitivity threshold of the methodology used, and the level of pro-inflammatory activation of the microglial cells that are being analyzed. In addition, cytoplasmatic and membrane Nox subunits were located in dopaminergic neurons, astrocytes and microglia (Rodriguez-Pallares et al.,,; Joglar et al., ).

A Major Role for The NADPH-Oxidase Complex Activation in Polarization to Proinflammatory/M1 Phenotype

The complex NADPH-oxidase is a multi-component enzyme constituted by three cytosolic subunits (p40, p47 and p67) and at least two membrane subunits (gp91 and p22). The complex is inactive when the different subunits are spatially isolated. After stimulation, the complex is assembled and activated. In cells, mitochondria and the membrane NADPH-oxidase complex are the major sources of ROS (Babior, ). In addition, NADPH oxidase-derived ROS enhance production of ROS by mitochondria, intracellular iron uptake and other intracellular ROS sources (Cai, ). It is known that there is a ROS-mediated cross-talk signaling between the membrane Nox and mitochondria (Sheh et al.,; Alberici et al., ). This feed-forward mechanism enhances and sustains ROS production. Most cells appear to have Nox. However, Nox produces high levels of oxidants in phagocytes and low levels of ROS, particularly for signaling function, in other cell types (including neurons and glial cells). Initially, Nox-derived ROS may have been developed in cells as a signaling system, and then specialized as a defense system in macrophages (Babior, ). In phagocytes-neutrophiles and monocytes, Nox produces high levels of extracellular superoxide/ROS to eliminate invading microorganisms or unwanted cells (Babior,; West et al., ). Superoxide induces tissue damage after being transformed into toxic species such as hydrogen peroxide and peroxynitrite, formed after reaction with NO. Furthermore, in the presence of Nox, iNOS oxidation of L-arginine (L-ARG) produces NO (MacMicking et al., ). ROS derived from Nox may also act indirectly by enhancing the production of proteases (Reeves et al., ). In macrophages and microglial cells, Nox-derived ROS also act on intracellular signaling pathways involved in microglial or macrophage activation and the release of proinflammatory signals (Qin et al., ).

Ang II, Via AT1 Receptors, Is A Major Activator of The NADPH-Oxidase Complex. Role in Brain Diseases and Neurodegeneration

Abnormal upregulation of local Ang II induces OS and exacerbates inflammation. As indicated above, Ang II, via its AT1 receptor, is a major activator of the NADPH-oxidase complex (Zalba et al.,; Hoogwerf, ), and NADPH-dependent oxidases mediate several key aspects of OS and inflammatory processes that are involved in major degenerative diseases in peripheral tissues (Griendling et al.,; Münzel and Keaney, ). In the brain, the RAS has been involved in several disorders such as anxiety and stress (Peng et al., ), depressive illness (Saab et al., ), and alcohol intake (Maul et al., ). Inhibition of AT1 receptors has been reported to improve aging-related deficits in learning, spatial working memory and motor performance (Hellner et al.,; Kerr et al., ). AT1 receptor blockers and ACE inhibitors (ACEIs) have been shown to inhibit inflammation in the central nervous system (Platten et al.,; Stegbauer et al., ). Indeed, AT1 receptor antagonists exerted positive effects in several processes mediated by microglial activation and neuroinflammation, such as experimental models of multiple sclerosis (Platten et al.,; Stegbauer et al., ), Alzheimer’s disease (AD; Kehoe and Wilcock,; Mogi and Horiuchi,; Torika et al., ) and brain ischemia (Iwanami et al., ). Consistent with this, several clinical and genetic studies suggest a relationship between AD and RAS (reviewed in Savaskan,; Kehoe and Wilcock,; Mogi and Horiuchi, ). In a series of recent studies in animal models of PD, we have also observed that the brain RAS plays a major role in progression of dopaminergic degeneration.

A number of experimental and clinical data suggest that neuroinflammation is a factor for the progression of dopaminergic neuron degeneration. Both PD patients (Ouchi et al.,; Ghadery et al., ) and PD animal models (Cicchetti et al.,; Rodriguez-Pallares et al., ) show enhanced microglial reaction in the substantia nigra and striatum (Figure 2). It was initially considered that the increase in the microglial response was a consequence of the neuronal death to remove dead cells and debris, although this inflammatory process may also lead to additional damage of the surrounding neurons and progression of neurodegeneration, as reported for several autoimmune diseases (Vowinckel et al., ). However, it has been shown that microglial response and Nox activation are major factors for triggering neuronal degeneration, acting synergistically with different pathogenic factors to induce neurodegeneration at early stages of the disease (Gao et al.,; Wu et al., ). In different PD models, we observed that Ang II increased the neurotoxic effect of low doses of dopaminergic neurotoxins, and that administration of ACE inhibitors (Lopez-Real et al.,; Muñoz et al., ) or AT1 receptor antagonists (Rey et al.,; Rodriguez-Pallares et al.,; Joglar et al., ) induced significant protection of dopaminergic neurons and reduction in neurotoxin-induced levels of protein oxidation and lipid peroxidation (Sánchez-Iglesias et al., ). Nox inhibitors also blocked the enhancing effect of Ang II on dopaminergic neurodegeneration, which confirmed that Nox activation and Nox-induced ROS play a major role in the Ang II-induced increase in neuronal loss (Rey et al.,; Rodriguez-Pallares et al.,; Joglar et al., ). In summary (Labandeira-Garcia et al.,; Labandeira-García et al., ), we suggest that Ang II acts by a double mechanism; in dopaminergic neurons (i.e., CNS resident cells), Ang II acts on AT1 receptors to produce low levels of intraneuronal ROS by activation of neuronal Nox. In addition, Ang II acts on microglia (i.e., inflammatory cells), and activation of the microglial AT1/ Nox axis induces the generation of high levels of superoxide and superoxide-derived ROS that, after being released to the extracellular medium, may lead to neuronal damage. In addition, a small amount of microglial ROS is used as a microglial second messenger in intracellular pathways that regulate the inflammatory response (Babior,; Qin et al., ). Consistent with this, overactivation of the Ang II/AT1/Nox axis enhances vulnerability of dopaminergic neurons and synergistically contributes to initiation and progression of the disease. The role of brain RAS in dopaminergic neuron death and possibly in PD has also been shown by a number of studies from different research groups (Grammatopoulos et al.,; Zawada et al.,; Sonsalla et al., ).

Overactivation of The Ang II/At1/NADPH-Oxidase Axis in Aging

Aging is the major risk factor for neurodegenerative diseases, and particularly for PD and AD (McCormack et al.,; Collier et al., ). Aged tissues, including brain tissue, are characterized by a proinflammatory, pro-oxidant state that leads to exacerbated responses to lesions and enhanced vulnerability to neurodegeneration (Csiszar et al.,; Choi et al., ). Consistent with this, age-related diseases such as hypertension, diabetes and atherosclerosis show increased NADPH-oxidase activity (Griendling et al.,; Mehta and Griendling, ). It is known that tissue Ang II, acting on AT1 receptors, plays a major role in inflammatory processes that induce age-related degenerative changes (Heymes et al.,; Basso et al., ). In normal non-pathological states, there is a tight regulation of Ang II-induced ROS (de Cavanagh et al.,; Garrido and Griendling, ). However, a marked hyperactivity of the Ang/AT1/Nox axis has been observed in aged tissues (Min et al.,; Cassis et al., ). Consistent with this, mice null for AT1 receptors showed longevity, which was related to a decrease in OS together with an increase in expression of the prosurvival gene sirtuin 3 and mitochondrial protection (Benigni et al.,; de Cavanagh et al.,; Valenzuela et al., ). Furthermore, AT1 receptor deletion decreased age-related progression of atherosclerosis (Umemoto, ).

We observed that the increase in AT1/Nox activity in the substantia nigra of aged rats plays a major role in the increase in vulnerability of dopaminergic neurons with aging (Figure 3). In aged animals, neurotoxins induced higher levels of dopaminergic neuron loss than in young animals (Sugama et al.,; McCormack et al., ), and nigral RAS was involved in this effect (Villar-Cheda et al., ). A significant increase in Nox activity and levels of the pro-inflammatory cytokines IL-1β and TNF-α was observed in aged rats, which revealed a pro-oxidative and pro-inflammatory state in the aged substantia nigra. Aged rats also showed upregulation of AT1 receptor expression and down-regulation of AT2 receptor expression, which was inhibited by administration of the AT1 receptor blocker candesartan. The aging-related increase in AT1 receptors may lead to the increase in the Nox-derived OS and dopaminergic cell vulnerability to degeneration. In aged rats, Nox activation is further increased by the lack of the compensatory upregulation of AT2 receptors (see below), which was observed in young rats after upregulation of AT1 receptor signaling (Villar-Cheda et al., ). Aging-related loss of striatal D2 and D1 receptors (Wang et al.,; Ishibashi et al., ) and alteration of the dopaminergic system (Kubis et al.,; Collier et al.,; Cruz-Muros et al., ) have been observed in experimental models and human brains. It is also known that Ang II, via AT1 receptors, increases the release of dopamine (Mendelsohn et al.,; Brown et al.,; Dominguez-Meijide et al., ). Therefore, the upregulation of the Ang II/AT1/Nox axis that we observed in aged rats may be a compensatory change to counteract the decreased levels of dopamine or dopamine receptors (Villar-Cheda et al.,, ). However, in addition to the dopaminergic down-regulation, other factors are probably involved in the aging-related upregulation of AT1/Nox activity, as aging has been shown to be associated with overactivation of the AngII/AT1/Nox axis in different tissues (Thompson et al.,; Min et al.,; Cassis et al., ).

The Role of Other Angiotensin Receptors in Regulation of Microglial Polarization

Level of Nox activation has been suggested to be a major factor for regulation of the shift between proinflammatory/M1 and M2/immunoregulatory microglial phenotypes, so that Nox activation promotes proinflammatory and suppress the immunoregulatory phenotype (Choi et al., ). Consistent with this, AT1 receptor antagonists reduce proinflammatory microglia activation and promote immunoregulatory microglia polarization (Saavedra,; Rodriguez-Perez et al.,; Torika et al., ). The classical Ang II/AT1/Nox pro-oxidative and pro-inflammatory axis plays a major role in the RAS effects both in the brain and peripheral tissues. However, it is now known that these effects are regulated by a RAS opposite arm constituted by Ang II/AT2 receptor signaling and Ang1–7/MasR signaling. A number of recent data suggest that activation of AT2 and/or MasRs plays an anti-oxidative/anti-inflammatory role. In addition, activation of PRR appears to contribute to activation of proinflammatory phenotype. However, the mechanisms involved in the interaction between different RAS receptors signaling to regulate microglial polarization and neuroinflammation are still unclear (Figure 4).

AT2 receptors counteract the effects of AT1 receptor activation and promote the M2/immunoregulatory phenotype. Reciprocal interaction between AT1 and AT2 receptors may regulate the effect of Ang II on cells (Sohn et al., ). Several studies in different types of cells have shown that AT2 activation decreases AT1 expression and NADPH-oxidase activation, leading to decrease in inflammatory responses (Jin et al.,; Yang et al.,; Lu et al., ). However, the intracellular pathways responsible for the interactions have not been clarified, and several mechanisms may be involved (Wu et al.,; Rompe et al.,; Yang et al.,; Dhande et al., ). Consistent with this, treatment with AT2 agonists led to reduction in the inflammatory responses, which were increased in AT2 receptor KO mice (Dhande et al.,; Iwanami et al., ). In the nigrostriatal system of young animals, we observed that upregulation of AT1 receptors was accompanied by a simultaneous and apparently compensatory upregulation of AT2 receptors (Villar-Cheda et al., ). In the nigra and striatum of aged rats, there was an increase in the expression of AT1 receptors and Nox activation; however, there was a lack of compensatory increase in AT2 expression (Villar-Cheda et al.,, ). In aged animals, a decrease in AT2 receptor expression may lead to further increase in the pro-oxidative, pro-inflammatory effects and neuron vulnerability induced by activation of upregulated AT1 receptors.

MasRs, together with AT2 receptors, are considered major components of the RAS protective arm, which mediates actions opposing to AT1 (Bader,; Villela et al., ). The ACE2 transforms Ang II into the heptapeptide Ang (1–7), which activates MasRs. It was observed that Mas-protooncogene is primarily expressed in the brain (Bunnemann et al.,; Von Bohlen und Halbach et al., ), and MasRs were identified in neurons, astrocytes and glial cells (Gallagher et al.,; Liu et al., ). Several recent studies suggest that activation of the Ang (1–7)/Mas axis inhibits the M1 inflammatory response in microglial cells and peripheral macrophages (Hammer et al.,; Liu et al.,; Tao et al., ). However, the cellular mechanisms involved in these effects remain to be clarified.

PRRs have been identified in neurons, astrocytes and microglial cells in rodents and primates, including humans (Valenzuela et al.,; Garrido-Gil et al., ). PRR, together with AT1 receptors, promote the inflammatory response and the M1/proinflammatory phenotype (Shi et al.,; Zhu et al., ). The mechanisms involved in interactions of PRR and other RAS receptors to regulate microglial polarization remain to be investigated. The peptide Ang IV and its receptor have been involved in a number of functions in the CNS (Wright et al., ). There are a few data on possible involvement of Ang IV in inflammatory responses in peripheral tissues (Esteban et al.,; Kong et al., ). However, there are no data on the involvement of Ang IV in the neuroinflammatory response.

Interactions Between RAS and Other Microglial Polarization Regulators

A number of studies have shown interactions or mutual regulation between RAS and different compounds involved in neuroinflammation and microglial polarization, such as estrogens, Rho kinase (ROCK), insulin-like growth factor-1 (IGF-1), TNF-α, iron, peroxisome proliferator-activated receptor gamma (PPARγ), and TLRs.

Estrogens protect neurons by mechanisms that are still unclear. However, modulation of the glial neuroinflammatory response plays a major role in the estrogen-induced neuroprotection (Morale et al.,; Suzuki et al.,; Vegeto et al., ). In several recent studies using PD models, we observed that estrogens modulate brain RAS and neuroinflammation acting both on astrocytes and microglia (Rodriguez-Perez et al.,,,; Labandeira-Garcia et al., ). We observed that activation of microglial estrogen receptor (ER) β with the agonist 2,3-Bis-4-hydroxyphenyl-propionitrile (DPN)) inhibited the Ang II-induced increase in levels of several major mediators of the microglial inflammatory response such as IL-1β and ROCK (Villar-Cheda et al.,; Rodriguez-Perez et al.,, ).

RhoA/ROCK is a major modulator of the actin cytoskeleton, which regulates migration of microglia and other inflammatory cells (Yan et al.,; Labandeira-Garcia et al., ) into lesioned areas (Greenwood et al.,; Honing et al., ). RhoA/ROCK induces changes in the actin cytoskeleton necessary for cell motility, process retraction and cell spreading, which characterize activation of inflammatory cells, including microglia (Bernhart et al., ). Activation of the microglial RhoA/ROCK pathway plays a major role in the effect of Ang II/AT1/Nox axis on microglial polarization and neurodegeneration. This was shown in rodents (Barcia et al.,; Villar-Cheda et al., ), and confirmed using mesencephalic cultures lacking microglial cells (Villar-Cheda et al.,; Borrajo et al., ). During Ang II-induced microglial activation, a crosstalk signaling between Nox and ROCK has been observed: Ang II-induced Nox activation led to superoxide production, NF-κB translocation and Rho-kinase activation. In addition, Rho-kinase activation was involved in regulation of NADPH-oxidase activation via p38 mitogen-activated protein kinase. Moreover, Rho-kinase activation, via NF-κB, upregulated angiotensin type-1 receptor expression in microglial cells through a feed-forward mechanism (Rodriguez-Perez et al., ).

For many years, IGF-1 was considered a cytoprotective factor. However, it has also been suggested that IGF-1 may be detrimental to health, and that reduced IGF-1 levels lead to prolonged life (Tao et al.,; Suh et al., ). Local brain IGF-1 is produced by neurons and glial cells (Quesada et al.,; Suh et al., ), but the effects of IGF-1 in the brain and particularly in the aged brain are unclear (Bartke et al.,; Brown-Borg, ). Inhibitory effects on the neuroinflammatory response (Nadjar et al., ), improvement in mitochondrial function (Puche et al., ), inhibition of OS and Sirtuin-1 activation (Vinciguerra et al.,; Tran et al., ) have been suggested as possible mechanisms. Interestingly, the brain RAS has been shown to be involved in neuroinflammation (Borrajo et al.,; Rodriguez-Perez et al., ), mitochondrial function (Zawada et al.,; Rodriguez-Pallares et al., ) and Sirtuin-1 activity (Diaz-Ruiz et al., ). Recently, we observed a reciprocal regulation between IGF-1 and RAS (Rodriguez-Perez et al., ): IGF-1 inhibited AT1/Nox activity in neurons and glial cells (i.e., it decreased AT1, increased AT2 and decreased angiotensinogen expression); conversely, Ang II—via AT1 receptors—increased the levels of IGF-1 in microglial cells, while activation of AT2 receptors decreased IGF-1 levels. We observed that Ang II, via AT1 receptors, induced an increase in markers of the proinflammatory phenotype, which was blocked by treatment with IGF-1, suggesting that induction of microglial IGF-1 by Ang II and other OS and pro-inflammatory inducers may play a major role in repressing the M1-neurotoxic phenotype and transition to an M2-repair/regenerative phenotype. Our study showed that IGF-1 and the local RAS interact to inhibit or activate neuroinflammation (i.e., transition from the M1/proinflammatory to the M2/immunoregulatory phenotype). However, in brains from aged rats, particularly in the substantia nigra, we observed increased Ang II/AT1/Nox activity, while IGF-I levels remained decreased. The loss of the mechanism that upregulates IGF-1 to inhibit the AT1/Nox axis (Rodriguez-Perez et al., ) may lead to the loss of capacity of microglia to undergo M2/immunoregulatory activation and the pro-oxidative and pro-inflammatory state that characterizes the aged brain, and particularly the aged substantia nigra (Rey et al.,; Villar-Cheda et al., ). IGF-1 and the local RAS may interact to inhibit or activate neuroinflammation and this important mechanism may be impaired in aged animals.

TNF-α is a pro-inflammatory cytokine that is involved in the pathogenesis of several neurodegenerative diseases (Hofman et al.,; Fillit et al.,; Mogi et al., ). In particular, dopaminergic neurons are highly vulnerable to TNF-α (McGuire et al.,; Qin et al.,; Harms et al., ). In primary mesencephalic cultures, we have recently observed that administration of low doses of the neurotoxin MPP+ led to significant dopaminergic cell death, which was increased by co-treatment with Ang II and decreased by administration of TNF-α blockers (Borrajo et al., ). Furthermore, treatment with Ang II induced a marked increase in levels of TNF-α in primary mesencephalic cultures, which was blocked by administration of AT1 receptor antagonists, NADPH-oxidase inhibitors and NFK-β blockers. In cultures lacking microglial cells, however, levels of TNF-α were not significantly affected by administration of Ang II. We also observed that AT1 receptors, NADPH-oxidase, Rho-kinase and NFK-β were involved in the release of TNF-α by microglia (Borrajo et al., ). These results revealed an important functional interaction between Ang II and TNF-α, and also that microglial TNF-α is a major mediator of Ang II-induced neuroinflammation and dopaminergic neurodegeneration.

Microglia play a major role in iron storage and homeostasis, and Ang II modulates microglial ferritin/iron storage levels and the neuroinflammatory response (Garrido-Gil et al., ). Microglial ferritin levels (i.e., iron storage by ferritin) change in response to OS and microglial activation, and the release of iron from ferritin in activated microglia may enhance the oxidative damage derived from the proinflammatory microglial response (Mehlhase et al., ). Consistent with this, we observed in PD models that intense RAS overactivity and OS induced an increase in microglial labile iron and a decrease in ferritin levels. Although some data are controversial (Zecca et al., ), it is usually accepted that iron and ferritin increase in the substantia nigra with aging (Dusek et al., ). Aging-related increase in microglial ferritin has been associated to a less efficient control of iron homeostasis by senescent microglia (Lopes et al., ). In several studies in aged rats, we observed hyperactivity of the AT1/Nox axis in the substantia nigra, together with an increase in the levels of iron and ferritin, which were inhibited by AT1 receptor blockers such as candesartan. This suggests that overactivity of the Ang II/AT1/Nox axis plays a key role in aging-related iron and ferritin increase in the substantia nigra (Garrido-Gil et al., ). The aging-associated upregulation of Ang II/AT1/Nox activity may lead to upregulation of iron storage by microglia and induce a pro-oxidative pro-inflammatory state and higher vulnerability of dopaminergic cells to degeneration with aging (Collier et al.,; Villar-Cheda et al.,, ).

PPAR-γ is a member of a group of nuclear receptors (PPARs), which have been related to regulation of macrophage and adipocyte differentiation, as well as glucose and lipid metabolism and energy homeostasis. PPAR-γ receptors are also involved in inhibition of expression of different inflammatory cytokines and downregulation of the inflammatory process (Jiang et al.,; Ricote et al., ). PPAR-γ receptors are also involved in regulation of microglial activation and suppression of the proinflammatory phenotype (Bernardo et al.,; Mrak and Landreth, ). It was also shown that activation of the PPAR-γ induces the microglial immunoregulatory/M2 phenotype (Benoit et al.,; Rajaram et al., ). PPARγ agonists have been suggested as promising therapy for neurodegenerative diseases enhanced by neuroinflammation such as AD and PD (Schintu et al.,; Mandrekar-Colucci et al., ). Several studies have shown that AT1 receptor antagonists activate PPARγ. This has been related to pharmacological properties of some AT1 blockers such as telmisartan (Xu et al., ). However, studies using AT1 null mice revealed that blockage of AT1 receptors, independently of the pharmacological properties of the antagonists, also inhibits neuroinflammation and neurodegeneration (Garrido-Gil et al., ). Inhibition of AT1 with antagonists (ARBs), in addition to inhibition of proinflammatory polarization (see above), leads to activation of PPAR-γ and promotes the immunoregulatory phenotype by a double mechanism: by a pharmacological AT1-independent PPARγ agonistic effect (with more or less activation potency depending on the type of ARB), and by a direct effect of the blockage of the AT1 itself, which also induces PPARγ activation (Garrido-Gil et al., ). Among ARBS, the role of PPARγ activation in anti-inflammatory effects is particularly important for telmisartan, both at peripheral and CNS levels (Garrido-Gil et al.,; Pang et al.,; Wang et al.,; Villapol and Saavedra, ).

TLRs such as TLR2 and TLR4 are known to mediate classical microglial activation and neuroinflammation (Rietdijk et al., ). An increasing number of studies suggest a functional interaction or crosstalk between AT1 receptors and TLR4 and/or TLR2 (Biancardi et al., ). AT1 receptor antagonists inhibit TLRs in different immune effector cells both in peripheral tissues (Dasu et al.,; Cheng et al., ) and in brain microglia (Daniele et al.,; Biancardi et al., ). Ang II, via AT1, has been shown to increase TLR4 expression and Ang II-mediated ROS production and Ang II-induced microglial activation was blunted in TLR4 deficient mice (Rietdijk et al., ). The mechanisms involved in Ang II/AT1/TLRs interactions remain unknown.

Several recent studies suggest a pivotal role of metabolic reprogramming in the regulation of the innate inflammatory response (Galván-Peña and O’Neill,; Tannahill et al., ). In the context of the peripheral immune cells, a shift in the cellular metabolism from oxidative phosphorylation to a erobic glycolysis for energy production favors the polarization toward a proinflammatory phenotype. More recently, the link between polarization and mitochondrial energy metabolism has been considered in microglia (see for review Orihuela et al., ). Interestingly, we have recently shown that an intracellular RAS, including AT1 and AT2 receptors, exists in brain mitochondria (Valenzuela et al., ). Activation of mitochondrial AT1 receptors regulates (by activation of mitochondrial Nox4) levels of superoxide and increases mitochondrial respiration. Mitochondrial AT2 receptors are much more abundant and downregulate mitochondrial respiration via NO production. Interestingly, altered expression of mitochondrial angiotensin receptors was observed in aged rats. Altered expression of AT1 and AT2 receptors with aging may contribute to mitochondrial dysfunction, neuroinflammation and neurodegeneration.

Conclusion

Dysregulation of brain RAS plays a major role in aging-related changes and neurodegeneration by exacerbation of OS and neuroinflammation, which may be attenuated by pharmacological manipulation of RAS components. Angiotensin II (via AT1 receptor and Nox activation) and prorenin/renin (via PRR) induce pro-inflammatory effects and M1 microglial phenotype. These effects are counteracted by a RAS opposite arm constituted by angiotensin II/AT2 receptor signaling and Angiotensin 1–7/MasR signaling, which promote anti-inflammatory effects and M2 microglial phenotype. In addition, there are interactions between RAS and different compounds involved in neuroinflammation and microglial polarization, such as estrogens, ROCK, IGF1, TNF-α, iron, PPARγ and TLRs. Pharmacological manipulation of brain RAS components may be an interesting therapeutical approach for neurodegenerative diseases and aging-related processes in which OS and neuroinflammation play a major role.

Author Contributions

All authors have contributed to this work and approved its final version for submission. JLL-G developed the idea for this review article and wrote the manuscript. AIR-P prepared the figures and was involved in literature review, and revision of the manuscript. JLL prepared the viral vectors used for activation of microglia in Figure 2, and revised the manuscript. PG-G, JR-P and MJG were involved in literature review, and preparation of the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 229

  1. 1.

    Alberici L. C. Oliveira H. C. Paim B. A. Mantello C. C. Augusto A. C. Zecchin K. G.. (2009 ). Mitochondrial ATP-sensitive K+ channels as redox signals to liver mitochondria in response to hypertriglyceridemia. Free Radic. Biol. Med. 47, 1432–1439.

    Not in our library10.1016/j.freeradbiomed.2009.08.013

  2. 2.

    Albiston A. L. McDowall S. G. Matsacos D. Sim P. Clune E. Mustafa T.. (2001 ). Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 276, 48623–48626.

    Not in our library10.1074/jbc.c100512200

  3. 3.

    Alliot F. Godin I. Pessac B. (1999 ). Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Dev. Brain Res. 117, 145–152.

    Not in our library10.1016/s0165-3806(99)00113-3

  4. 4.

    Babior B. M. (2004 ). NADPH oxidase. Curr. Opin. Immunol. 16, 42–47.

    Not in our library10.1016/j.coi.2003.12.001

  5. 5.

    Bacani C. Frishman W. H. (2006 ). Chymase: a new pharmacologic target in cardiovascular disease. Cardiol. Rev. 14, 187–193.

    Not in our library10.1097/01.crd.0000195220.62533.c5

  6. 6.

    Bader M. (2013 ). ACE2, angiotensin-(1–7), and Mas: the other side of the coin. Pflugers Arch. 465, 79–85.

    Not in our library10.1007/s00424-012-1120-0

  7. 7.

    Balakumar P. Jagadeesh G. (2014 ). A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cell. Signal. 26, 2147–2160.

    Not in our library10.1016/j.cellsig.2014.06.011

  8. 8.

    Barcia C. Ros C. M. Annese V. Carrillo-de Sauvage M. A. Ros-Bernal F. Gómez A.. (2012 ). ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Sci. Rep. 2:809.

    Not in our library10.1038/srep00809

  9. 9.

    Bartke A. Chandrashekar V. Dominici F. Turyn D. Kinney B. Steger R.. (2003 ). Insulin-like growth factor 1 (IGF-1) and aging: controversies and new insights. Biogerontology 4, 1–8.

    Not in our library10.1023/a:1022448532248

  10. 10.

    Basso N. Paglia N. Stella I. de Cavanagh E. M. Ferder L. del Rosario Lores Arnaiz M.. (2005 ). Protective effect of the inhibition of the renin-angiotensin system on aging. Regul. Pept. 128, 247–252.

    Not in our library10.1016/j.regpep.2004.12.027

  11. 11.

    Benicky J. Sánchez-Lemus E. Pavel J. Saavedra J. M. (2009 ). Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell. Mol. Neurobiol. 29, 781–792.

    Not in our library10.1007/s10571-009-9368-4

  12. 12.

    Benigni A. Corna D. Zoja C. Sonzogni A. Latini R. Salio M.. (2009 ). Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 119, 524–530.

    Not in our library10.1172/jci36703

  13. 13.

    Benoit M. Desnues B. Mege J. L. (2008 ). Macrophage polarization in bacterial infections. J. Immunol. 181, 3733–3739.

    Not in our library10.4049/jimmunol.181.6.3733

  14. 14.

    Bernardo A. Levi G. Minghetti L. (2000 ). Role of the peroxisome proliferator-activated receptor-γ (PPAR-γ) and its natural ligand 15-deoxy-∆12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12, 2215–2223.

    Not in our library10.1046/j.1460-9568.2000.00110.x

  15. 15.

    Bernhart E. Kollroser M. Rechberger G. Reicher H. Heinemann A. Schratl P.. (2010 ). Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics 10, 141–158.

    Not in our library10.1002/pmic.200900195

  16. 16.

    Biancardi V. C. Stranahan A. M. Krause E. G. de Kloet A. D. Stern J. E. (2016 ). Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus. Am. J. Physiol. Heart Circ. Physiol. 310, H404–H415.

    Not in our library10.1152/ajpheart.00247.2015

  17. 17.

    Borrajo A. Rodriguez-Perez A. I. Diaz-Ruiz C. Guerra M. J. Labandeira-Garcia J. L. (2014a ). Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia 62, 145–157.

    Not in our library10.1002/glia.22595

  18. 18.

    Borrajo A. Rodriguez-Perez A. I. Villar-Cheda B. Guerra M. J. Labandeira-Garcia J. L. (2014b ). Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. Neuropharmacology 85, 1–8.

    Not in our library10.1016/j.neuropharm.2014.05.021

  19. 19.

    Brown D. C. Steward L. J. Ge J. Barnes N. M. (1996 ). Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br. J. Pharmacol. 118, 414–420.

    Not in our library10.1111/j.1476-5381.1996.tb15418.x

  20. 20.

    Brown-Borg H. M. (2007 ). Hormonal regulation of longevity in mammals. Ageing Res. Rev. 6, 28–45.

    Not in our library10.1016/j.arr.2007.02.005

  21. 21.

    Bunnemann B. Fuxe K. Metzger R. Mullins J. Jackson T. R. Hanley M. R.. (1990 ). Autoradiographic localization of mas proto-oncogene mRNA in adult rat brain using in situ hybridization. Neurosci. Lett. 114, 147–153.

    Not in our library10.1016/0304-3940(90)90063-f

  22. 22.

    Butovsky O. Jedrychowski M. P. Moore C. S. Cialic R. Lanser A. J. Gabriely G.. (2014 ). Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat. Neurosci. 17, 131–143.

    Not in our library10.1038/nn.3599

  23. 23.

    Cai H. (2005 ). NAD(P)H oxidase–dependent self-propagation of hydrogen peroxide and vascular disease. Circ. Res. 96, 818–822.

    Not in our library10.1161/01.res.0000163631.07205.fb

  24. 24.

    Carson M. J. Doose J. M. Melchior B. Schmid C. D. Ploix C. C. (2006 ). CNS immune privilege: hiding in plain sight. Immunol. Rev. 213, 48–65.

    Not in our library10.1111/j.1600-065x.2006.00441.x

  25. 25.

    Cassis P. Conti S. Remuzzi G. Benigni A. (2010 ). Angiotensin receptors as determinants of life span. Pflugers Arch. 459, 325–332.

    Not in our library10.1007/s00424-009-0725-4

  26. 26.

    Chabrashvili T. Kitiyakara C. Blau J. Karber A. Aslam S. Welch W. J.. (2003 ). Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase and SOD expression. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R117–R124.

    Not in our library10.1152/ajpregu.00476.2002

  27. 27.

    Cheng X. W. Song H. Sasaki T. Hu L. Inoue A. Bando Y. K.. (2011 ). Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Hypertension 57, 981–989.

    Not in our library10.1161/hypertensionaha.110.168385

  28. 28.
    Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro · 2013
    No notice
  29. 29.

    Choi S.-H. Aid S. Kim H.-W. Jackson S. H. Bosetti F. (2012 ). Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J. Neurochem. 120, 292–301.

    Not in our library10.1111/j.1471-4159.2011.07572.x

  30. 30.

    Choi D.-Y. Zhang J. Bing G. (2010 ). Aging enhances the neuroinflammatory response and α-synuclein nitration in rats. Neurobiol. Aging 31, 1649–1653.

    Not in our library10.1016/j.neurobiolaging.2008.09.010

  31. 31.

    Cicchetti F. Brownell A. L. Williams K. Chen Y. I. Livni E. Isacson O. (2002 ). Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15, 991–998.

    Not in our library10.1046/j.1460-9568.2002.01938.x

  32. 32.

    Clark M. A. Diz D. I. Tallant E. A. (2001 ). Angiotensin-(1–7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 37, 1141–1146.

    Not in our library10.1161/01.hyp.37.4.1141

  33. 33.

    Collier T. J. Lipton J. Daley B. F. Palfi S. Chu Y. Sortwell C.. (2007 ). Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 26, 56–65.

    Not in our library10.1016/j.nbd.2006.11.013

  34. 34.

    Colton C. A. (2009 ). Heterogeneity of microglial activation in the innate immune response in the brain. J. Neuroimmune Pharmacol. 4, 399–418.

    Not in our library10.1007/s11481-009-9164-4

  35. 35.

    Cruz-Muros I. Afonso-Oramas D. Abreu P. Pérez-Delgado M. M. Rodriguez M. González-Hernández T. (2009 ). Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol. Aging 30, 973–986.

    Not in our library10.1016/j.neurobiolaging.2007.09.009

  36. 36.

    Csiszar A. Ungvari Z. Koller A. Edwards J. G. Kaley G. (2003 ). Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J. 17, 1183–1185.

    Not in our library10.1096/fj.02-1049fje

  37. 37.

    Daniele S. G. Béraud D. Davenport C. Cheng K. Yin H. Maguire-Zeiss K. A. (2015 ). Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci. Signal. 8:ra45.

    Not in our library10.1126/scisignal.2005965

  38. 38.

    Dasu M. R. Riosvelasco A. C. Jialal I. (2009 ). Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 202, 76–83.

    Not in our library10.1016/j.atherosclerosis.2008.04.010

  39. 39.

    Davalos D. Grutzendler J. Yang G. Kim J. V. Zuo Y. Jung S.. (2005 ). ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752–758.

    Not in our library10.1038/nn1472

  40. 40.

    de Cavanagh E. M. Inserra F. Ferder L. (2011 ). Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc. Res. 89, 31–40.

    Not in our library10.1093/cvr/cvq285

  41. 41.

    de Cavanagh E. M. Piotrkowski B. Fraga C. G. (2004 ). Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging. Mol. Aspects Med. 25, 27–36.

    Not in our library10.1016/j.mam.2004.02.006

  42. 42.

    Dhande I. Ali Q. Hussain T. (2013 ). Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension 61, 1218–1226.

    Not in our library10.1161/hypertensionaha.111.00422

  43. 43.

    Diaz-Ruiz C. Rodriguez-Perez A. I. Beiroa D. Rodriguez-Pallares J. Labandeira-Garcia J. L. (2015 ). Reciprocal regulation between sirtuin-1 and angiotensin-II in the substantia nigra: implications for aging and neurodegeneration. Oncotarget 6, 26675–26689.

    Not in our library10.18632/oncotarget.5596

  44. 44.

    Dominguez-Meijide A. Rodriguez-Perez A. I. Diaz-Ruiz C. Guerra M. J. Labandeira-Garcia J. L. (2017 ). Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures. Brain Behav. Immun. 62, 277–290.

    Not in our library10.1016/j.bbi.2017.02.013

  45. 45.

    Dominguez-Meijide A. Villar-Cheda B. Garrido-Gil P. Sierrra-Paredes G. Guerra M. J. Labandeira-Garcia J. L. (2014 ). Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson’s disease treated with L-DOPA. Neuropharmacology 76, 156–168.

    Not in our library10.1016/j.neuropharm.2013.07.016

  46. 46.

    Dusek P. Jankovic J. Le W. (2012 ). Iron dysregulation in movement disorders. Neurobiol. Dis. 46, 1–18.

    Not in our library10.1016/j.nbd.2011.12.054

  47. 47.

    Edwards J. P. Zhang X. Frauwirth K. A. Mosser D. M. (2006 ). Biochemical and functional characterization of three activated macrophage populations. J. Leukoc. Biol. 80, 1298–1307.

    Not in our library10.1189/jlb.0406249

  48. 48.

    Esteban V. Ruperez M. Sánchez-López E. Rodriguez-Vita J. Lorenzo O. Demaegdt H.. (2005 ). Angiotensin IV activates the nuclear transcription factor-κB and related proinflammatory genes in vascular smooth muscle cells. Circ. Res. 96, 965–973.

    Not in our library10.1161/01.res.0000166326.91395.74

  49. 49.

    Fillit H. Ding W. H. Buee L. Kalman J. Altstiel L. Lawlor B.. (1991 ). Elevated circulating tumor necrosis factor levels in Alzheimer’s disease. Neurosci. Lett. 129, 318–320.

    Not in our library10.1016/0304-3940(91)90490-k

  50. 50.

    Franco R. Fernández-Suárez D. (2015 ). Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131, 65–86.

    Not in our library10.1016/j.pneurobio.2015.05.003

  51. 51.
    Does neuroinflammation fan the flame in neurodegenerative diseases? · 2009
    No notice
  52. 52.

    Fujisaka S. Usui I. Kanatani Y. Ikutani M. Takasaki I. Tsuneyama K.. (2011 ). Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice. Endocrinology 152, 1789–1799.

    Not in our library10.1210/en.2010-1312

  53. 53.

    Gallagher P. E. Chappell M. C. Ferrario C. M. Tallant E. A. (2006 ). Distinct roles for ANG II and ANG-(1–7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am. J. Physiol. Cell Physiol. 290, C420–C426.

    Not in our library10.1152/ajpcell.00409.2004

  54. 54.
    Metabolic Reprograming in Macrophage Polarization · 2014
    No notice
  55. 55.

    Ganong W. F. (1994 ). Origin of the angiotensin II secreted by cells. Proc. Soc. Exp. Biol. Med. 205, 213–219.

    Not in our library10.3181/00379727-205-43699a

  56. 56.

    Gao H. M. Liu B. Zhang W. Hong J. S. (2003 ). Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease. FASEB J. 17, 1954–1956.

    Not in our library10.1096/fj.03-0109fje

  57. 57.

    Garrido A. M. Griendling K. K. (2009 ). NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 302, 148–158.

    Not in our library10.1016/j.mce.2008.11.003

  58. 58.

    Garrido-Gil P. Joglar B. Rodriguez-Perez A. I. Guerra M. J. Labandeira-Garcia J. L. (2012 ). Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson’s disease. J. Neuroinflammation 9:38.

    Not in our library10.1186/1742-2094-9-38

  59. 59.

    Garrido-Gil P. Rodriguez-Pallares J. Dominguez-Meijide A. Guerra M. J. Labandeira-Garcia J. L. (2013a ). Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells. Exp. Neurol. 250, 384–396.

    Not in our library10.1016/j.expneurol.2013.10.013

  60. 60.

    Garrido-Gil P. Valenzuela R. Villar-Cheda B. Lanciego J. L. Labandeira-Garcia J. L. (2013b ). Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra. Brain Struct. Funct. 218, 373–388.

    Not in our library10.1007/s00429-012-0402-9

  61. 61.

    Garrido-Gil P. Rodriguez-Perez A. I. Fernandez-Rodriguez P. Lanciego J. L. Labandeira-Garcia J. L. (2017 ). Expression of angiotensinogen and receptors for angiotensin and prorenin in the rat and monkey striatal neurons and glial cells. Brain Struct. Funct. [Epub ahead of print].

    Not in our library10.1007/s00429-016-1357-z

  62. 62.

    Gautier E. L. Shay T. Miller J. Greter M. Jakubzick C. Ivanov S.. (2012 ). Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 1118–1128.

    Not in our library10.1038/ni.2419

  63. 63.

    Ghadery C. Koshimori Y. Coakeley S. Harris M. Rusjan P. Kim J.. (2017 ). Microglial activation in Parkinson’s disease using [18F]-FEPPA. J. Neuroinflammation 14:8.

    Not in our library10.1186/s12974-016-0778-1

  64. 64.

    Ginhoux F. Greter M. Leboeuf M. Nandi S. See P. Gokhan S.. (2010 ). Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841–845.

    Not in our library10.1126/science.1194637

  65. 65.

    Gordon S. (2003 ). Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23–35.

    Not in our library10.1038/nri978

  66. 66.
    Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra · 2007
    No notice
  67. 67.

    Greenwood J. Walters C. E. Pryce G. Kanuga N. Beraud E. Baker D.. (2003 ). Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17, 905–907.

    Not in our library10.1096/fj.02-1014fje

  68. 68.

    Griendling K. K. Sorescu D. Ushio-Fukai M. (2000 ). NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86, 494–501.

    Not in our library10.1161/01.res.86.5.494

  69. 69.

    Hammer A. Yang G. Friedrich J. Kovacs A. Lee D. H. Grave K.. (2016 ). Role of the receptor Mas in macrophage-mediated inflammation in vivo. Proc. Natl. Acad. Sci. U S A 113, 14109–14114.

    Not in our library10.1073/pnas.1612668113

  70. 70.

    Hamming I. Cooper M. E. Haagmans B. L. Hooper N. M. Korstanje R. Osterhaus A. D.. (2007 ). The emerging role of ACE2 in physiology and disease. J. Pathol. 212, 1–11.

    Not in our library10.1002/path.2162

  71. 71.

    Harding J. W. Sullivan M. J. Hanesworth J. M. Cushing L. L. Wright J. W. (1988 ). Inability of [125I]Sar1, Ile8-angiotensin II to move between the blood and cerebrospinal fluid compartments. J. Neurochem. 50, 554–557.

    Not in our library10.1111/j.1471-4159.1988.tb02946.x

  72. 72.

    Harms A. S. Lee J. K. Nguyen T. A. Chang J. Ruhn K. M. Treviño I.. (2012 ). Regulation of microglia effector functions by tumor necrosis factor signaling. Glia 60, 189–202.

    Not in our library10.1002/glia.21254

  73. 73.

    Harrison J. K. Jiang Y. Chen S. Xia Y. Maciejewski D. McNamara R. K.. (1998 ). Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc. Natl. Acad. Sci. U S A 95, 10896–10901.

    Not in our library10.1073/pnas.95.18.10896

  74. 74.

    Harry G. J. Kraft A. D. (2012 ). Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 33, 191–206.

    Not in our library10.1016/j.neuro.2012.01.012

  75. 75.

    Hellner K. Walther T. Schubert M. Albrecht D. (2005 ). Angiotensin-(1–7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol. Cell. Neurosci. 29, 427–435.

    Not in our library10.1016/j.mcn.2005.03.012

  76. 76.

    Heneka M. T. Carson M. J. El Khoury J. Landreth G. E. Brosseron F. Feinstein D. L.. (2015 ). Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14, 388–405.

    Not in our library10.1016/s1474-4422(15)70016-5

  77. 77.

    Herrera M. Silva G. B. Garvin J. L. (2010 ). Angiotensin II stimulates thick ascending limb superoxide production via protein kinase Cα-dependent NADPH oxidase activation. J. Biol. Chem. 285, 21323–21328.

    Not in our library10.1074/jbc.m110.109157

  78. 78.

    Heymes C. Silvestre J. S. Llorens-Cortes C. Chevalier B. Marotte F. Levy B. I.. (1998 ). Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology 139, 2579–2587.

    Not in our library10.1210/en.139.5.2579

  79. 79.

    Hickman S. E. Kingery N. D. Ohsumi T. K. Borowsky M. L. Wang L. C. Means T. K.. (2013 ). The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 16, 1896–1905.

    Not in our library10.1038/nn.3554

  80. 80.

    Hoek R. M. Ruuls S. R. Murphy C. A. Wright G. J. Goddard R. Zurawski S. M.. (2000 ). Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 290, 1768–1771.

    Not in our library10.1126/science.290.5497.1768

  81. 81.

    Hofman F. M. Hinton D. R. Johnson K. Merrill J. E. (1989 ). Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170, 607–612.

    Not in our library10.1084/jem.170.2.607

  82. 82.

    Honing H. van den Berg T. K. van der Pol S. M. Dijkstra C. D. van der Kammen R. A. Collard J. G.. (2004 ). RhoA activation promotes transendothelial migration of monocytes via ROCK. J. Leukoc. Biol. 75, 523–528.

    Not in our library10.1189/jlb.0203054

  83. 83.

    Hoogwerf B. J. (2010 ). Renin-angiotensin system blockade and cardiovascular and renal protection. Am. J. Cardiol. 105, 30A–35A.

    Not in our library10.1016/j.amjcard.2009.10.009

  84. 84.

    Hu X. Liou A. K. Leak R. K. Xu M. An C. Suenaga J.. (2014 ). Neurobiology of microglial action in CNS injuries: receptor-mediated signaling mechanisms and functional roles. Prog. Neurobiol. 119–120, 60–84.

    Not in our library10.1016/j.pneurobio.2014.06.002

  85. 85.

    Ishibashi K. Ishii K. Oda K. Kawasaki K. Mizusawa H. Ishiwata K. (2009 ). Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse 63, 282–290.

    Not in our library10.1002/syn.20603

  86. 86.

    Iwanami J. Mogi M. Tsukuda K. Min L. J. Sakata A. Jing F.. (2010 ). Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-γ activation in diabetic mice. J. Hypertens. 28, 1730–1737.

    Not in our library10.1097/hjh.0b013e32833a551a

  87. 87.

    Iwanami J. Mogi M. Tsukuda K. Wang X.-L. Nakaoka H. Kan-no H.. (2015 ). Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia. J. Am. Soc. Hypertens. 9, 250–256.

    Not in our library10.1016/j.jash.2015.01.010

  88. 88.

    Jiang C. Ting A. T. Seed B. (1998 ). PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82–86.

    Not in our library10.1038/34184

  89. 89.

    Jin C. Z. Jang J. H. Wang Y. Kim J. G. Bae Y. M. Shi J.. (2012 ). Neuronal nitric oxide synthase is up-regulated by angiotensin II and attenuates NADPH oxidase activity and facilitates relaxation in murine left ventricular myocytes. J. Mol. Cell. Cardiol. 52, 1274–1281.

    Not in our library10.1016/j.yjmcc.2012.03.013

  90. 90.

    Joglar B. Rodriguez-Pallares J. Rodriguez-Perez A. I. Rey P. Guerra M. J. Labandeira-Garcia J. L. (2009 ). The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 109, 656–669.

    Not in our library10.1111/j.1471-4159.2009.05999.x

  91. 91.

    Jones E. S. Vinh A. McCarthy C. A. Gaspari T. A. Widdop R. E. (2008 ). AT2 receptors: functional relevance in cardiovascular disease. Pharmacol. Ther. 120, 292–316.

    Not in our library10.1016/j.pharmthera.2008.08.009

  92. 92.

    Kehoe P. G. Wilcock G. K. (2007 ). Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol. 6, 373–378.

    Not in our library10.1016/s1474-4422(07)70077-7

  93. 93.

    Kerr D. S. Bevilaqua L. R. Bonini J. S. Rossato J. I. Köhler C. A. Medina J. H.. (2005 ). Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism. Psychopharmacology (Berl) 179, 529–535.

    Not in our library10.1007/s00213-004-2074-5

  94. 94.

    Kettenmann H. Hanisch U.-K. Noda M. Verkhratsky A. (2011 ). Physiology of microglia. Physiol. Rev. 91, 461–553.

    Not in our library10.1152/physrev.00011.2010

  95. 95.

    Kigerl K. A. Gensel J. C. Ankeny D. P. Alexander J. K. Donnelly D. J. Popovich P. G. (2009 ). Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29, 13435–13444.

    Not in our library10.1523/jneurosci.3257-09.2009

  96. 96.

    Kim J. Y. Kim N. Yenari M. A. (2015 ). Mechanisms and potential therapeutic applications of microglial activation after brain injury. CNS Neurosci. Ther. 21, 309–319.

    Not in our library10.1111/cns.12360

  97. 97.

    Koenigsknecht-Talboo J. Landreth G. E. (2005 ). Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25, 8240–8249.

    Not in our library10.1523/jneurosci.1808-05.2005

  98. 98.

    Kong J. Zhang K. Meng X. Zhang Y. Zhang C. (2015 ). Dose-dependent bidirectional effect of angiotensin IV on abdominal aortic aneurysm via variable angiotensin receptor stimulation. Hypertension 66, 617–626.

    Not in our library10.1161/hypertensionaha.115.05482

  99. 99.

    Kostenis E. Milligan G. Christopoulos A. Sanchez-Ferrer C. F. Heringer-Walther S. Sexton P. M.. (2005 ). G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111, 1806–1813.

    Not in our library10.1161/01.cir.0000160867.23556.7d

  100. 100.

    Kubis N. Faucheux B. A. Ransmayr G. Damier P. Duyckaerts C. Henin D.. (2000 ). Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123, 366–373.

    Not in our library10.1093/brain/123.2.366

  101. 101.

    Kumar A. Rassoli A. Raizada M. K. (1988 ). Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain. J. Neurosci. Res. 19, 287–290.

    Not in our library10.1002/jnr.490190302

  102. 102.

    Labandeira-García J. L. Garrido-Gil P. Rodriguez-Pallares J. Valenzuela R. Borrajo A. Rodríguez-Perez A. I. (2014 ). Brain renin-angiotensin system and dopaminergic cell vulnerability. Front. Neuroanat. 8:67.

    Not in our library10.3389/fnana.2014.00067

  103. 103.

    Labandeira-Garcia J. L. Rodriguez-Pallares J. Dominguez-Meijide A. Valenzuela R. Villar-Cheda B. Rodriguez-Perez A. I. (2013 ). Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson’s disease. Mov. Disord. 28, 1337–1342.

    Not in our library10.1002/mds.25614

  104. 104.

    Labandeira-Garcia J. L. Rodriguez-Perez A. I. Valenzuela R. Costa-Besada M. A. Guerra M. J. (2016 ). Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration. Front. Neuroendocrinol. 43, 44–59.

    Not in our library10.1016/j.yfrne.2016.09.003

  105. 105.

    Labandeira-Garcia J. L. Rodríguez-Perez A. I. Villar-Cheda B. Borrajo A. Dominguez-Meijide A. Guerra M. J. (2015 ). Rho kinase and dopaminergic degeneration: a promising therapeutic target for Parkinson’s disease. Neuroscientist 21, 616–629.

    Not in our library10.1177/1073858414554954

  106. 106.

    Lawson L. J. Perry V. H. Dri P. Gordon S. (1990 ). Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151–170.

    Not in our library10.1016/0306-4522(90)90229-w

  107. 107.

    Liu M. Shi P. Sumners C. (2016 ). Direct anti-inflammatory effects of angiotensin-(1–7) on microglia. J. Neurochem. 136, 163–171.

    Not in our library10.1111/jnc.13386

  108. 108.

    Liu J. Zhang P.-S. Yu Q. Liu L. Yang Y. Guo F.-M.. (2012 ). Losartan inhibits conventional dendritic cell maturation and Th1 and Th17 polarization responses: novel mechanisms of preventive effects on lipopolysaccharide-induced acute lung injury. Int. J. Mol. Med. 29, 269–276.

    Not in our library10.3892/ijmm.2011.818

  109. 109.

    Lopes K. O. Sparks D. L. Streit W. J. (2008 ). Microglial dystrophy in the aged and Alzheimer’s disease brain is associated with ferritin immunoreactivity. Glia 56, 1048–1060.

    Not in our library10.1002/glia.20678

  110. 110.

    Lopez-Real A. Rey P. Soto-Otero R. Mendez-Alvarez E. Labandeira-Garcia J. L. (2005 ). Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J. Neurosci. Res. 81, 865–873.

    Not in our library10.1002/jnr.20598

  111. 111.

    Lu J. Wu L. Jiang T. Wang Y. Zhao H. Gao Q.. (2015 ). Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson’s disease in CATH.a cells. Neurotoxicol. Teratol. 47, 16–24.

    Not in our library10.1016/j.ntt.2014.11.004

  112. 112.

    Ma L.-J. Corsa B. A. Zhou J. Yang H. Li H. Tang Y.-W.. (2011 ). Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am. J. Physiol. Renal Physiol. 300, F1203–F1213.

    Not in our library10.1152/ajprenal.00468.2010

  113. 113.

    MacMicking J. Xie Q. W. Nathan C. (1997 ). Nitric oxide and macrophage function. Annu. Rev. Immunol. 15, 323–350.

    Not in our library10.1146/annurev.immunol.15.1.323

  114. 114.

    Mandrekar-Colucci S. Karlo J. C. Landreth G. E. (2012 ). Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J. Neurosci. 32, 10117–10128.

    Not in our library10.1523/jneurosci.5268-11.2012

  115. 115.

    Mantovani A. Sica A. Sozzani S. Allavena P. Vecchi A. Locati M. (2004 ). The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686.

    Not in our library10.1016/j.it.2004.09.015

  116. 116.

    Maul B. Krause W. Pankow K. Becker M. Gembardt F. Alenina N.. (2005 ). Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 19, 1474–1481.

    Not in our library10.1096/fj.05-3742com

  117. 117.

    McCormack A. L. Di Monte D. A. Delfani K. Irwin I. DeLanney L. E. Langston W. J.. (2004 ). Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471, 387–395.

    Not in our library10.1002/cne.20036

  118. 118.

    McGuire S. O. Ling Z. D. Lipton J. W. Sortwell C. E. Collier T. J. Carvey P. M. (2001 ). Tumor necrosis factor α is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169, 219–230.

    Not in our library10.1006/exnr.2001.7688

  119. 119.

    Mehlhase J. Gieche J. Widmer R. Grune T. (2006 ). Ferritin levels in microglia depend upon activation: modulation by reactive oxygen species. Biochim. Biophys. Acta 1763, 854–859.

    Not in our library10.1016/j.bbamcr.2006.04.012

  120. 120.

    Mehta P. K. Griendling K. K. (2007 ). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82–C97.

    Not in our library10.1152/ajpcell.00287.2006

  121. 121.

    Mendelsohn F. A. Jenkins T. A. Berkovic S. F. (1993 ). Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rats. Brain Res. 613, 221–229.

    Not in our library10.1016/0006-8993(93)90902-y

  122. 122.

    Milsted A. Barna B. P. Ransohoff R. M. Brosnihan K. B. Ferrario C. M. (1990 ). Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA. Proc. Natl. Acad. Sci. U S A 87, 5720–5723.

    Not in our library10.1073/pnas.87.15.5720

  123. 123.

    Min L. J. Mogi M. Iwai M. Horiuchi M. (2009 ). Signaling mechanisms of angiotensin II in regulating vascular senescence. Ageing Res. Rev. 8, 113–121.

    Not in our library10.1016/j.arr.2008.12.002

  124. 124.

    Mittelbronn M. Dietz K. Schluesener H. J. Meyermann R. (2001 ). Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. 101, 249–255.

    Not in our library10.1007/s004010000284

  125. 125.

    Miyoshi M. Miyano K. Moriyama N. Taniguchi M. Watanabe T. (2008 ). Angiotensin type 1 receptor antagonist inhibits lipopolysaccharide-induced stimulation of rat microglial cells by suppressing nuclear factor κB and activator protein-1 activation. Eur. J. Neurosci. 27, 343–351.

    Not in our library10.1111/j.1460-9568.2007.06014.x

  126. 126.

    Mogi M. Harada M. Riederer P. Narabayashi H. Fujita K. Nagatsu T. (1994 ). Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208–210.

    Not in our library10.1016/0304-3940(94)90746-3

  127. 127.

    Mogi M. Horiuchi M. (2009 ). Effects of angiotensin II receptor blockers on dementia. Hypertens. Res. 32, 738–740.

    Not in our library10.1038/hr.2009.110

  128. 128.

    Morale M. C. Serra P. A. L’Episcopo F. Tirolo C. Caniglia S. Testa N.. (2006 ). Estrogen, neuroinflammation and neuroprotection in Parkinson’s disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 138, 869–878.

    Not in our library10.1016/j.neuroscience.2005.07.060

  129. 129.

    Mrak R. E. Landreth G. E. (2004 ). PPARγ, neuroinflammation and disease. J. Neuroinflammation 1:5.

    Not in our library10.1186/1742-2094-1-5

  130. 130.

    Muñoz A. Rey P. Guerra M. J. Mendez-Alvarez E. Soto-Otero R. Labandeira-Garcia J. L. (2006 ). Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51, 112–120.

    Not in our library10.1016/j.neuropharm.2006.03.004

  131. 131.

    Münzel T. Keaney J. F. Jr. (2001 ). Are ACE inhibitors a “magic bullet” against oxidative stress? Circulation 104, 1571–1574.

    Not in our library10.1161/hc3801.095585

  132. 132.

    Nadjar A. Berton O. Guo S. Leneuve P. Dovero S. Diguet E.. (2009 ). IGF-1 signaling reduces neuro-inflammatory response and sensitivity of neurons to MPTP. Neurobiol. Aging 30, 2021–2030.

    Not in our library10.1016/j.neurobiolaging.2008.02.009

  133. 133.

    Nguyen G. (2011 ). Renin, (pro)renin and receptor: an update. Clin. Sci. (Lond) 120, 169–178.

    Not in our library10.1042/cs20100432

  134. 134.

    Nguyen G. Contrepas A. (2008 ). The (pro)renin receptors. J. Mol. Med. (Berl) 86, 643–646.

    Not in our library10.1007/s00109-008-0319-1

  135. 135.

    Nguyen G. Delarue F. Burcklé C. Bouzhir L. Giller T. Sraer J. D. (2002 ). Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417–1427.

    Not in our library10.1172/jci0214276

  136. 136.

    Nimmerjahn A. Kirchhoff F. Helmchen F. (2005 ). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314–1318.

    Not in our library10.1126/science.1110647

  137. 137.

    Orihuela R. McPherson C. A. Harry G. J. (2016 ). Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 173, 649–665.

    Not in our library10.1111/bph.13139

  138. 138.

    Oro C. Qian H. Thomas W. G. (2007 ). Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol. Ther. 113, 210–226.

    Not in our library10.1016/j.pharmthera.2006.10.001

  139. 139.

    Ouchi Y. Yoshikawa E. Sekine Y. Futatsubashi M. Kanno T. Ogusu T.. (2005 ). Microglial activation and dopamine terminal loss in early Parkinson’s disease. Ann. Neurol. 57, 168–175.

    Not in our library10.1002/ana.20338

  140. 140.

    Pang T. Benicky J. Wang J. Orecna M. Sanchez-Lemus E. Saavedra J. M. (2012 ). Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes. J. Hypertens. 30, 87–96.

    Not in our library10.1097/hjh.0b013e32834dde5f

  141. 141.

    Peng J. Kimura B. Phillips M. I. (2002 ). The predominant role of brain angiotensinogen and angiotensin in environmentally induced hypertension. Regul. Pept. 110, 25–32.

    Not in our library10.1016/s0167-0115(02)00156-8

  142. 142.

    Phillips M. I. de Oliveira E. M. (2008 ). Brain renin angiotensin in disease. J. Mol. Med. (Berl) 86, 715–722.

    Not in our library10.1007/s00109-008-0331-5

  143. 143.

    Platten M. Youssef S. Hur E. M. Ho P. P. Han M. H. Lanz T. V.. (2009 ). Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl. Acad. Sci. U S A 106, 14948–14953.

    Not in our library10.1073/pnas.0903958106

  144. 144.

    Plumb R. D. El-Sherbeeny N. A. Dixon L. J. Hughes S. M. Devine A. B. Leahey W. J.. (2005 ). NAD(P)H-dependent superoxide production in platelets: the role of angiotensin II and protein kinase C. Clin. Biochem. 38, 607–613.

    Not in our library10.1016/j.clinbiochem.2005.04.012

  145. 145.

    Porrini V. Lanzillotta A. Branca C. Benarese M. Parrella E. Lorenzini L.. (2015 ). CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to β-amyloid. Neuroscience 302, 112–120.

    Not in our library10.1016/j.neuroscience.2014.10.029

  146. 146.

    Prinz M. Priller J. (2014 ). Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat. Rev. Neurosci. 15, 300–312.

    Not in our library10.1038/nrn3722

  147. 147.

    Puche J. E. García-Fernández M. Muntané J. Rioja J. González-Barón S. Castilla Cortazar I. (2008 ). Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 149, 2620–2627.

    Not in our library10.3748/wjg.14.2731

  148. 148.

    Qin L. Liu Y. Wang T. Wei S. J. Block M. L. Wilson B.. (2004 ). NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 279, 1415–1421.

    Not in our library10.1074/jbc.m307657200

  149. 149.

    Qin L. Wu X. Block M. L. Liu Y. Breese G. R. Hong J. S.. (2007 ). Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55, 453–462.

    Not in our library10.1002/glia.20467

  150. 150.

    Quesada A. Romeo H. E. Micevych P. (2007 ). Distribution and localization patterns of estrogen receptor-β and insulin-like growth factor-1 receptors in neurons and glial cells of the female rat substantia nigra: localization of ERβ and IGF-1R in substantia nigra. J. Comp. Neurol. 503, 198–208.

    Not in our library10.1002/cne.21358

  151. 151.

    Rajaram M. V. Brooks M. N. Morris J. D. Torrelles J. B. Azad A. K. Schlesinger L. S. (2010 ). Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor γ linking mannose receptor recognition to regulation of immune responses. J. Immunol. 185, 929–942.

    Not in our library10.4049/jimmunol.1000866

  152. 152.

    Ransohoff R. M. Brown M. A. (2012 ). Innate immunity in the central nervous system. J. Clin. Invest. 122, 1164–1171.

    Not in our library10.1172/jci58644

  153. 153.

    Ransohoff R. M. Perry V. H. (2009 ). Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119–145.

    Not in our library10.1146/annurev.immunol.021908.132528

  154. 154.

    Re R. N. (2004 ). Tissue renin angiotensin systems. Med. Clin. North Am. 88, 19–38.

    Not in our library10.1016/s0025-7125(03)00124-x

  155. 155.

    Reeves E. P. Lu H. Jacobs H. L. Messina C. G. Bolsover S. Gabella G.. (2002 ). Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 416, 291–297.

    Not in our library10.1038/416291a

  156. 156.

    Rey P. Lopez-Real A. Sanchez-Iglesias S. Muñoz A. Soto-Otero R. Labandeira-Garcia J. L. (2007 ). Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 28, 555–567.

    Not in our library10.1016/j.neurobiolaging.2006.02.018

  157. 157.

    Ricote M. Li A. C. Willson T. M. Kelly C. J. Glass C. K. (1998 ). The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79–82.

    Not in our library10.1038/34178

  158. 158.

    Rietdijk C. D. Van Wezel R. J. A. Garssen J. Kaneveld A. D. (2016 ). Neuronal toll-like receptors and neuro-immunity in Parkinson’s disease, Alzheimer’s disease and stroke. Neuroimmunol. Neuroinflammation 3, 27–37.

    Not in our library10.20517/2347-8659.2015.28

  159. 159.

    Rodriguez-Pallares J. Parga J. A. Joglar B. Guerra M. J. Labandeira-Garcia J. L. (2012 ). Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson’s disease. Age (Dordr) 34, 863–880.

    Not in our library10.1007/s11357-011-9284-7

  160. 160.

    Rodriguez-Pallares J. Parga J. A. Muñoz A. Rey P. Guerra M. J. Labandeira-Garcia J. L. (2007 ). Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J. Neurochem. 103, 145–156.

    Not in our library10.1111/j.1471-4159.2007.04699.x

  161. 161.

    Rodriguez-Pallares J. Quiroz C. R. Parga J. A. Guerra M. J. Labandeira-Garcia J. L. (2004 ). Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur. J. Neurosci. 20, 1489–1498.

    Not in our library10.1111/j.1460-9568.2004.03621.x

  162. 162.

    Rodriguez-Pallares J. Rey P. Parga J. A. Muñoz A. Guerra M. J. Labandeira-Garcia J. L. (2008 ). Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 31, 58–73.

    Not in our library10.1016/j.nbd.2008.03.003

  163. 163.

    Rodriguez-Perez A. I. Borrajo A. Diaz-Ruiz C. Garrido-Gil P. Labandeira-Garcia J. L. (2016 ). Crosstalk between insulin-like growth factor-1 and angiotensin-II in dopaminergic neurons and glial cells: role in neuroinflammation and aging. Oncotarget 7, 30049–30067.

    Not in our library10.18632/oncotarget.9174

  164. 164.

    Rodriguez-Perez A. I. Borrajo A. Rodriguez-Pallares J. Guerra M. J. Labandeira-Garcia J. L. (2015a ). Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation. Glia 63, 466–482.

    Not in our library10.1002/glia.22765

  165. 165.

    Rodriguez-Perez A. I. Borrajo A. Valenzuela R. Lanciego J. L. Labandeira-Garcia J. L. (2015b ). Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats. Neurobiol. Aging 36, 1194–1208.

    Not in our library10.1016/j.neurobiolaging.2014.10.028

  166. 166.
    Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease · 2013
    Not checked
  167. 167.

    Rodriguez-Perez A. I. Valenzuela R. Villar-Cheda B. Guerra M. J. Labandeira-Garcia J. L. (2012 ). Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system. Brain 135, 124–138.

    Not in our library10.1093/brain/awr320

  168. 168.

    Rodriguez-Perez A. I. Valenzuela R. Villar-Cheda B. Guerra M. J. Lanciego J. L. Labandeira-Garcia J. L. (2010 ). Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson’s disease. Exp. Neurol. 224, 517–526.

    Not in our library10.1016/j.expneurol.2010.05.015

  169. 169.

    Rompe F. Artuc M. Hallberg A. Alterman M. Ströder K. Thöne-Reineke C.. (2010 ). Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55, 924–931.

    Not in our library10.1161/hypertensionaha.109.147843

  170. 170.

    Ruiz-Ortega M. Lorenzo O. Suzuki Y. Rupérez M. Egido J. (2001 ). Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 10, 321–329.

    Not in our library10.1097/00041552-200105000-00005

  171. 171.

    Saab Y. B. Gard P. R. Yeoman M. S. Mfarrej B. El-Moalem H. Ingram M. J. (2007 ). Renin-angiotensin-system gene polymorphisms and depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 1113–1118.

    Not in our library10.1016/j.pnpbp.2007.04.002

  172. 172.

    Saavedra J. M. (2012 ). Angiotensin II AT1 receptor blockers as treatments for inflammatory brain disorders. Clin. Sci. 123, 567–590.

    Not in our library10.1042/cs20120078

  173. 173.

    Sánchez-Iglesias S. Rey P. Méndez-Alvarez E. Labandeira-García J. L. Soto-Otero R. (2007 ). Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson’s disease. Neurochem. Res. 32, 99–105.

    Not in our library10.1007/s11064-006-9232-6

  174. 174.

    Santos R. A. Simoes e Silva A. C. Maric C. Silva D. M. Machado R. P. de Buhr I.. (2003 ). Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U S A 100, 8258–8263.

    Not in our library10.1073/pnas.1432869100

  175. 175.

    Savaskan E. (2005 ). The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr. Alzheimer Res. 2, 29–35.

    Not in our library10.2174/1567205052772740

  176. 176.

    Schintu N. Frau L. Ibba M. Caboni P. Garau A. Carboni E.. (2009 ). PPAR-γ-mediated neuroprotection in a chronic mouse model of Parkinson’s disease. Eur. J. Neurosci. 29, 954–963.

    Not in our library10.1111/j.1460-9568.2009.06657.x

  177. 177.

    Seshiah P. N. Weber D. S. Rocic P. Valppu L. Taniyama Y. Griendling K. K. (2002 ). Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 91, 406–413.

    Not in our library10.1161/01.res.0000033523.08033.16

  178. 178.

    Shan Z. Cuadra A. E. Sumners C. Raizada M. K. (2008 ). Characterization of a functional (pro)renin receptor in rat brain neurons. Exp. Physiol. 93, 701–708.

    Not in our library10.1113/expphysiol.2008.041988

  179. 179.

    Sheh Y. L. Hsu C. Chan S. H. Chan J. Y. (2007 ). NADPH oxidase- and mitochondrion-derived superoxide at rostral ventrolateral medulla in endotoxin-induced cardiovascular depression. Free Radic. Biol. Med. 42, 1610–1623.

    Not in our library10.1016/j.freeradbiomed.2007.02.019

  180. 180.

    Shi P. Grobe J. L. Desland F. A. Zhou G. Shen X. Z. Shan Z.. (2014 ). Direct pro-inflammatory effects of prorenin on microglia. PLoS One 9:e92937.

    Not in our library10.1371/journal.pone.0092937

  181. 181.

    Shrestha S. Noh J. M. Kim S. Y. Ham H. Y. Kim Y. J. Yun Y. J.. (2016 ). Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype. Oncoimmunology 5:e1067744.

    Not in our library10.1080/2162402x.2015.1067744

  182. 182.

    Sica A. Bronte V. (2007 ). Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155–1166.

    Not in our library10.1172/jci31422

  183. 183.

    Sica A. Mantovani A. (2012 ). Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787–795.

    Not in our library10.1172/jci59643

  184. 184.

    Sohn H. Y. Raff U. Hoffmann A. Gloe T. Heermeier K. Galle J.. (2000 ). Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br. J. Pharmacol. 131, 667–672.

    Not in our library10.1038/sj.bjp.0703566

  185. 185.

    Sonsalla P. K. Coleman C. Wong L. Y. Harris S. L. Richardson J. R. Gadad B. S.. (2013 ). The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism. Exp. Neurol. 250, 376–383.

    Not in our library10.1016/j.expneurol.2013.10.014

  186. 186.

    Stegbauer J. Lee D. H. Seubert S. Ellrichmann G. Manzel A. Kvakan H.. (2009 ). Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U S A 106, 14942–14947.

    Not in our library10.1073/pnas.0903602106

  187. 187.

    Stornetta R. L. Hawelu-Johnson C. L. Guyenet P. G. Lynch K. R. (1988 ). Astrocytes synthesize angiotensinogen in brain. Science 242, 1444–1446.

    Not in our library10.1126/science.3201232

  188. 188.

    Sugama S. Yang L. Cho B. P. DeGiorgio L. A. Lorenzl S. Albers D. S.. (2003 ). Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res. 964, 288–294.

    Not in our library10.1016/s0006-8993(02)04085-4

  189. 189.

    Suh Y. Atzmon G. Cho M. O. Hwang D. Liu B. Leahy D. J.. (2008 ). Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc. Natl. Acad. Sci. U S A 105, 3438–3442.

    Not in our library10.1073/pnas.0705467105

  190. 190.
    Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators · 2013
    No notice
  191. 191.

    Suzuki S. Brown C. M. Dela Cruz C. D. Yang E. Bridwell D. A. Wise P. M. (2007 ). Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc. Natl. Acad. Sci. U S A 104, 6013–6018.

    Not in our library10.1073/pnas.0610394104

  192. 192.

    Suzuki Y. Ruiz-Ortega M. Lorenzo O. Ruperez M. Esteban V. Egido J. (2003 ). Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35, 881–900.

    Not in our library10.1016/s1357-2725(02)00271-6

  193. 193.

    Tang Y. Le W. (2016 ). Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 53, 1181–1194.

    Not in our library10.1007/s12035-014-9070-5

  194. 194.

    Tannahill G. M. Iraci N. Gaude E. Frezza C. Pluchino S. (2015 ). Metabolic reprograming of mononuclear phagocytes in progressive multiple sclerosis. Front. Immunol. 6:106.

    Not in our library10.3389/fimmu.2015.00106

  195. 195.

    Tao Y. Pinzi V. Bourhis J. Deutsch E. (2007 ). Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol. 4, 591–602.

    Not in our library10.1038/ncponc0934

  196. 196.

    Tao L. Qiu Y. Fu X. Lin R. Lei C. Wang J.. (2016 ). Angiotensin-converting enzyme 2 activator diminazene aceturate prevents lipopolysaccharide-induced inflammation by inhibiting MAPK and NF-κB pathways in human retinal pigment epithelium. J. Neuroinflammation 13:35.

    Not in our library10.1186/s12974-016-0489-7

  197. 197.

    Thomas W. G. Greenland K. J. Shinkel T. A. Sernia C. (1992 ). Angiotensinogen is secreted by pure rat neuronal cell cultures. Brain Res. 588, 191–200.

    Not in our library10.1016/0006-8993(92)91575-y

  198. 198.

    Thompson M. M. Oyama T. T. Kelly F. J. Kennefick T. M. Anderson S. (2000 ). Activity and responsiveness of the renin-angiotensin system in the aging rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279, R1787–R1794.

    Not in our library10.1007/978-1-60761-186-8_16

  199. 199.

    Torika N. Asraf K. Roasso E. Danon A. Fleisher-Berkovich S. (2016 ). Angiotensin converting enzyme inhibitors ameliorate brain inflammation associated with microglial activation: possible implications for Alzheimer’s disease. J. Neuroimmune Pharmacol. 11, 774–785.

    Not in our library10.1007/s11481-016-9703-8

  200. 200.

    Touyz R. M. (2004 ). Reactive oxygen species and angiotensin II signaling in vascular cells—implications in cardiovascular disease. Braz. J. Med. Biol. Res. 37, 1263–1273.

    Not in our library10.1590/s0100-879x2004000800018

  201. 201.
    Insulin‐like growth factor‐1 regulates the SIRT 1‐p53 pathway in cellular senescence · 2014
    No notice
  202. 202.

    Umemoto S. (2008 ). Angiotensin II type 1 (AT1) receptor deficiency halts the progression of age-related atherosclerosis in hypercholesterolemia: molecular link between the AT1 receptor and hypercholesterolemia. Hypertens. Res. 31, 1495–1497.

    Not in our library10.1291/hypres.31.1495

  203. 203.

    Unger T. Chung O. Csikos T. Culman J. Gallinat S. Gohlke P.. (1996 ). Angiotensin receptors. J. Hypertens. Suppl. 14, S95–S103.

    Not in our library

  204. 204.

    Valenzuela R. Barroso-Chinea P. Villar-Cheda B. Joglar B. Muñoz A. Lanciego J. L.. (2010 ). Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. J. Neuropathol. Exp. Neurol. 69, 1130–1142.

    Not in our library10.1097/nen.0b013e3181fa0308

  205. 205.

    Valenzuela R. Costa-Besada M. A. Iglesias-Gonzalez J. Perez-Costas E. Villar-Cheda B. Garrido-Gil P.. (2016 ). Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration. Cell Death Dis. 7:e2427.

    Not in our library10.1038/cddis.2016.327

  206. 206.

    Vegeto E. Benedusi V. Maggi A. (2008 ). Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 29, 507–519.

    Not in our library10.1016/j.yfrne.2008.04.001

  207. 207.

    Villapol S. Saavedra J. M. (2015 ). Neuroprotective effects of angiotensin receptor blockers. Am. J. Hypertens. 28, 289–299.

    Not in our library10.1093/ajh/hpu197

  208. 208.

    Villar-Cheda B. Dominguez-Meijide A. Joglar B. Rodriguez-Perez A. I. Guerra M. J. Labandeira-Garcia J. L. (2012a ). Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol. Dis. 47, 268–279.

    Not in our library10.1016/j.nbd.2012.04.010

  209. 209.

    Villar-Cheda B. Valenzuela R. Rodriguez-Perez A. I. Guerra M. J. Labandeira-Garcia J. L. (2012b ). Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol. Aging 33, 204.e1–204.e11.

    Not in our library10.1016/j.neurobiolaging.2010.08.006

  210. 210.

    Villar-Cheda B. Dominguez-Meijide A. Valenzuela R. Granado N. Moratalla R. Labandeira-Garcia J. L. (2014 ). Aging-related dysregulation of dopamine and angiotensin receptor interaction. Neurobiol. Aging 35, 1726–1738.

    Not in our library10.1016/j.neurobiolaging.2014.01.017

  211. 211.

    Villar-Cheda B. Rodríguez-Pallares J. Valenzuela R. Muñoz A. Guerra M. J. Baltatu O. C.. (2010 ). Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson’s disease. Eur. J. Neurosci. 32, 1695–1706.

    Not in our library10.1111/j.1460-9568.2010.07448.x

  212. 212.

    Villar-Cheda B. Sousa-Ribeiro D. Rodriguez-Pallares J. Rodriguez-Perez A. I. Guerra M. J. Labandeira-Garcia J. L. (2009 ). Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson’s disease. J. Cereb. Blood Flow Metab. 29, 230–234.

    Not in our library10.1038/jcbfm.2008.127

  213. 213.

    Villela D. Leonhardt J. Patel N. Joseph J. Kirsch S. Hallberg A.. (2015 ). Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin. Sci. (Lond) 128, 227–234.

    Not in our library10.1042/cs20130515

  214. 214.

    Vinciguerra M. Santini M. P. Claycomb W. C. Ladurner A. G. Rosenthal N. (2009 ). Local IGF-1 isoform protects cardiomyocytes from hypertrophic and oxidative stresses via SirT1 activity. Aging (Albany NY) 2, 43–62.

    Not in our library10.18632/aging.100107

  215. 215.

    Von Bohlen und Halbach O. Walther T. Bader M. Albrecht D. (2000 ). Interaction between Mas and the angiotensin AT1 receptor in the amygdala. J. Neurophysiol. 83, 2012–2021.

    Not in our library10.1152/jn.2000.83.4.2012

  216. 216.

    Vowinckel E. Reutens D. Becher B. Verge G. Evans A. Owens T.. (1997 ). PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neurosci. Res. 50, 345–353.

    Not in our library10.1002/(sici)1097-4547(19971015)50:2<345::aid-jnr22>3.3.co;2-s

  217. 217.

    Wang Y. Chan G. L. Holden J. E. Dobko T. Mak E. Schulzer M.. (1998 ). Age-dependent decline of dopamine D1 receptors in human brain: a PET study. Synapse 30, 56–61.

    Not in our library10.1002/(sici)1098-2396(199809)30:1<56::aid-syn7>3.0.co;2-j

  218. 218.

    Wang J. Pang T. Hafko R. Benicky J. Sanchez-Lemus E. Saavedra J. M. (2014 ). Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation. Neuropharmacology 79, 249–261.

    Not in our library10.1016/j.neuropharm.2013.11.022

  219. 219.

    West A. P. Brodsky I. E. Rahner C. Woo D. K. Erdjument-Bromage H. Tempst P.. (2011 ). TLR signalling augments macrophage bactericidal activity through mitochondrial ROS. Nature 472, 476–480.

    Not in our library10.1038/nature09973

  220. 220.

    Wright J. W. Kawas L. H. Harding J. W. (2015 ). The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog. Neurobiol. 125, 26–46.

    Not in our library10.1016/j.pneurobio.2014.11.004

  221. 221.

    Wu L. Iwai M. Li Z. Shiuchi T. Min L. J. Cui T. X.. (2004 ). Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol. Endocrinol. 18, 666–678.

    Not in our library10.1210/me.2003-0053

  222. 222.

    Wu D. C. Teismann P. Tieu K. Vila M. Jackson-Lewis V. Ischiropoulos H.. (2003 ). NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Proc. Natl. Acad. Sci. U S A 100, 6145–6150.

    Not in our library10.1073/pnas.0937239100

  223. 223.

    Xu Y. Xu Y. Wang Y. Wang Y. He L. Jiang Z.. (2015 ). Telmisartan prevention of LPS-induced microglia activation involves M2 microglia polarization via CaMKKβ-dependent AMPK activation. Brain Behav. Immun. 50, 298–313.

    Not in our library10.1016/j.bbi.2015.07.015

  224. 224.

    Yan J. Zhou X. Guo J. J. Mao L. Wang Y. J. Sun J.. (2012 ). Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J. Neurochem. 120, 721–731.

    Not in our library10.1111/j.1471-4159.2011.07619.x

  225. 225.

    Yang J. Chen C. Ren H. Han Y. He D. Zhou L.. (2012 ). Angiotensin II AT(2) receptor decreases AT1 receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J. Hypertens. 30, 1176–1184.

    Not in our library10.1097/hjh.0b013e3283532099

  226. 226.

    Zalba G. San José G. Moreno M. U. Fortuño M. A. Fortuño A. Beaumont F. J.. (2001 ). Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension 38, 1395–1399.

    Not in our library10.1161/hy1201.099611

  227. 227.

    Zawada W. M. Banninger G. P. Thornton J. Marriott B. Cantu D. Rachubinski A. L.. (2011 ). Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J. Neuroinflammation 8:129.

    Not in our library10.1186/1742-2094-8-129

  228. 228.

    Zecca L. Gallorini M. Schünemann V. Trautwein A. X. Gerlach M. Riederer P.. (2001 ). Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76, 1766–1773.

    Not in our library10.1046/j.1471-4159.2001.00186.x

  229. 229.

    Zhu T. Miller A. G. Deliyanti D. Berka D. R. Agrotis A. Campbell D. J.. (2015 ). Prorenin stimulates a pro-angiogenic and pro-inflammatory response in retinal endothelial cells and an M1 phenotype in retinal microglia. Clin. Exp. Pharmacol. Physiol. 42, 537–548.

    Not in our library10.1111/1440-1681.12376

Cited by papers we hold 9

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.